

Author's response: understanding the natural progression in %FEV₁ decline in patients with cystic fibrosis: a longitudinal study

We thank Professor Miller for his comments¹ regarding our paper,² in which we outline a novel approach to modelling repeated lung function measures in people with cystic fibrosis (CF) over long follow-up periods. We agree that it would be interesting to apply our methodology using alternative methods of expressing lung function across the age range, and reiterate that our approach can be usefully applied to any clinical outcome measured repeatedly over extended periods.

While the merits of different approaches are appreciated, we chose to model forced expiratory volume in 1 s as a percentage of predicted (%FEV₁) for a number of reasons. First, %FEV₁ is still currently recognised as a key outcome measure in CF³ as it is predictive of survival, and is currently an important criterion in international lung transplant guidelines.⁴ Second, %FEV₁ has been modelled previously over long follow-up periods, across the paediatric and adult age range in CF using a random-intercept and slope approach,⁵ and we wanted to compare our method with this. Third, standardised %FEV₁ was the most commonly collected outcome measure in the Danish CF registry.

While we agree that use of recently developed all-age equations, such as those published by Stanojevic⁶ or Quanjer⁷ would be advantageous in avoiding arbitrary breaks, for the purposes of this analysis, we adhered to the approach that is currently used in Denmark to facilitate comparisons with previously published data. Irrespective of the precise outcome

used, our finding that the error in repeated measurements of %FEV₁ within individuals is large (average within-person SD of 6 percentage points) remains valid. Furthermore, our approach provides more realistic estimates of the underlying lung-function trajectory of people with chronic lung disease, by acknowledging the imprecision in individual measurements over time, and the correlation structure of repeated measurements on the same individual, issues that have all too often been disregarded in the past.

David Taylor-Robinson,¹ Margaret Whitehead,¹
Finn Diderichsen,² Hanne Veberth Olesen,³
Tania Pressler,⁴ Rosalind Smyth,⁵ Peter Diggle⁶

¹Department of Public Health and Policy, University of Liverpool, Liverpool, UK

²Department of Social Medicine, University of Copenhagen, Copenhagen, Denmark

³Cystic Fibrosis Center, Aarhus University Hospital, Aarhus, Denmark

⁴Cystic Fibrosis Center, Rigshospitalet, Copenhagen, Denmark

⁵Institute of Child Health, UCL, London, UK

⁶Institute of Infection and Global Health, University of Liverpool, Liverpool, UK

Correspondence to Dr David Taylor-Robinson, Department of Public Health and Policy, University of Liverpool, Liverpool, UK; dctr@liv.ac.uk

Funding DTR is supported by an MRC Population Health Scientist Fellowship (G0802448).

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

To cite Taylor-Robinson D, Whitehead M, Diderichsen F, *et al.* *Thorax* 2013;**68**:294–295.

Published Online First 4 December 2012



► <http://dx.doi.org/10.1136/thoraxjnl-2012-202838>

Thorax 2013;**68**:294–295.
doi:10.1136/thoraxjnl-2012-202954

REFERENCES

- 1 Miller M. FEV₁ decline in cystic fibrosis. *Thorax* 2012 doi:10.1136/thoraxjnl-2012-202838.
- 2 Taylor-Robinson D, Whitehead M, Diderichsen F, *et al.* Understanding the natural progression in %FEV₁ decline in patients with cystic fibrosis: a longitudinal study. *Thorax* 2012;**67**:860–6.
- 3 Rosenfeld M, Coates A, Corey M, *et al.* Task force to evaluate choice of spirometric reference equations for the National Patient Registry: summary and recommendations. Cystic Fibrosis Foundation Registry Committee, 1 Oct 2005.
- 4 Orens JB, Estenne M, Arcasoy S, *et al.* International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2006;**25**:745–55.
- 5 Corey M, Edwards L, Levison H, *et al.* Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. *J Pediatrics* 1997;**131**:809–14.

- 6 Stanojevic S, Wade A, Stocks J, *et al.* Reference ranges for spirometry across all ages: a new approach. *Am J Respir Crit Care Med* 2008;177:253–60.
- 7 Quanjer PH, Stanojevic S, Cole TJ, *et al.* Multi-ethnic reference values for spirometry for the 3–95 year age range: the global lung function 2012 equations. *Eur Respir J* Published Online First: 27 Jun 2012. doi: 10.1183/09031936.00080312.